What is the role of anticoagulation and antiplatelet agents in the treatment of moyamoya disease?

Updated: Nov 09, 2018
  • Author: Roy Sucholeiki, MD; Chief Editor: Amy Kao, MD  more...
  • Print

The rationale behind the administration of anticoagulation and antiplatelet agents is the prevention of further strokes, especially in stenotic vessels (where further infarction can occur if occlusion progresses).

These medications are not approved by the US Food and Drug Administration (FDA) specifically for use in moyamoya disease. Therefore, the decision to treat patients with anticoagulants such as heparin (and, in some cases, warfarin, for long-term anticoagulation) or antiplatelet agents such as aspirin rests on the following: angiogram findings, severity of stroke, and risk/benefit analysis by physicians who are experienced in stroke treatment.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!